(CBPO)

China Biologic Products, Inc.

Close Price:
26.20

Change:
0.2 Stock Price Increase0.20

% Change:
0.0076923076923076923076923077 Stock Price Increase0.77 %

Date:
5/9/2013

52 Week:
7.07 - 31.15

Prev Close:
26.00

Open:
26.04

Volume:
1,543

90D Avg. Volume:
51,074

5/9/2013 Range:
25.60 - 26.20

Market Cap:
702,684,000

Trailing PE Ratio:
16.17

Shares Out:
26,820,000

EPS:
1.62

Yield:
0.00

Dividend:
0.00

Dividend Date:
-

Quarter End:
6/30/2013

China Biologic Products, Inc.

Sector: Healthcare

Industry: Biotechnology

Website: www.chinabiologic.com

Business Summary: China Biologic Products, Inc., a biopharmaceutical company, through its subsidiaries, engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People?s Republic of China. It offers human albumin for the treatment of shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also offers human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human albumin and human immunoglobulin for intravenous injection (IVIG) products for original immunoglobulin deficiency, secondary immunoglobulin deficiency, and auto-immune deficiency diseases; and Thymopolypeptides injection that is used for the treatment of various original and secondary T-cell deficiency syndromes, auto-immune deficiency diseases, and a range of cell immunity deficiency diseases, as well as assists in the treatment for tumors. In addition, it provides human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; human tetanus immunoglobulin for the prevention and therapy of tetanus; and placenta polypeptide that is used for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia caused by various reasons, as well as assists in postoperative heating. The company?s products under development comprise human prothrombin complex concentrate; human hepatitis B immunoglobulin (PH4) for intravenous injection; human fibrinogen; Varicella hyperimmune globulins; and Human IVIG. It distributes its products directly or through distributors. The company is based in Beijing, the People's Republic of China.


Jialong International Building
18th Floor
Beijing, 100125 China ,
P: 86 10 6698 3166
F: 86 10 6598 3222

CBPO Earnings Calendar

Q1:
Dec
31
 -
Mar
30
Q2:
Mar
31
 -
Jun
30
Q3:
Jun
30
 -
Sep
29
Q4:
Sep
30
 -
Dec
30
Period Ending
 
Assets
Current Assets
Cash & Cash Equivalents
Short Term Investments
Net Receivables
Inventory
Other Current Assets
Total Current Assets
Long Term Assets
Property Plant & Equipment
Goodwill
Intangible Assets
Accumulated Amortization
Other Assets
Deferred Long Asset Charges
Total Assets
Liabilities
Current Liabilities
Accounts Payable
Short/Current Long Term Debt
Other Current Liabilities
Total Current Liabilities
Long Term Debt
Other Liabilities
Deferred Long Term Liability Charges
Minority Interest
Negative Goodwill
Total Liabilities
Stockholders' Equity
Misc Stock Options Warrants
Redeemable Preferred Stock
Preferred Stock
Common Stock
Retained Earnings
Treasury Stock
Capital Surplus
Other Stockholder Equity
Total Stockholder Equity
Net Tangible Assets
12/31/2009
 
 
 
$53,844
$0
$5,230
$35,133
$0
$95,506
$6,627
$28,873
$12,426
$21,180
$0
$3,224
$0
$167,836
 
 
$34,810
$10,371
$5,937
$51,118
$33,075
$0
$0
$33,130
$0
$117,323
 
$0
$0
$0
$2
$0
$0
$22,517
$22,692
$50,514
$16,908
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
YoY
 
 
 
510.8%
0.0%
540.1%
135.0%
0.0%
279.1%
1.4%
49.6%
0.0%
2,011.7%
0.0%
(78.7%)
0.0%
149.9%
 
 
104.0%
1,241.7%
443.7%
170.1%
463.7%
(100.0%)
0.0%
686.6%
0.0%
300.0%
 
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
110.4%
93.2%
33.5%
(54.1%)
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
12/31/2008
 
 
 
$8,815
$0
$817
$14,949
$0
$25,196
$6,534
$19,299
$0
$1,003
$0
$15,138
$0
$67,169
 
 
$17,064
$773
$1,092
$18,929
$5,868
$324
$0
$4,212
$0
$29,332
 
$0
$0
$0
$2
$0
$0
$10,700
$11,743
$37,837
$36,835
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
YoY
 
 
 
75.9%
0.0%
(23.9%)
57.3%
0.0%
60.2%
0.0%
25.0%
0.0%
9.5%
0.0%
1,132.7%
0.0%
101.7%
 
 
236.2%
(45.1%)
173.7%
175.1%
0.0%
128.2%
0.0%
8.4%
0.0%
168.9%
 
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
14.0%
64.9%
68.9%
71.5%
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
Period Ending
 
Assets
Current Assets
Cash & Cash Equivalents
Short Term Investments
Net Receivables
Inventory
Other Current Assets
Total Current Assets
Long Term Assets
Property Plant & Equipment
Goodwill
Intangible Assets
Accumulated Amortization
Other Assets
Deferred Long Asset Charges
Total Assets
Liabilities
Current Liabilities
Accounts Payable
Short/Current Long Term Debt
Other Current Liabilities
Total Current Liabilities
Long Term Debt
Other Liabilities
Deferred Long Term Liability Charges
Minority Interest
Negative Goodwill
Total Liabilities
Stockholders' Equity
Misc Stock Options Warrants
Redeemable Preferred Stock
Preferred Stock
Common Stock
Retained Earnings
Treasury Stock
Capital Surplus
Other Stockholder Equity
Total Stockholder Equity
Net Tangible Assets
6/30/2010
 
 
 
$56,263
$0
$9,299
$41,435
$0
$108,845
$7,002
$35,598
$12,426
$19,988
$0
$2,637
$0
$186,496
 
 
$34,470
$6,432
$4,051
$44,953
$22,506
$0
$0
$40,242
$0
$107,702
 
$0
$0
$0
$2
$0
$0
$28,071
$27,754
$78,794
$46,381
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
QoQ
 
 
 
13.7%
0.0%
191.1%
51.7%
0.0%
32.9%
8.1%
28.8%
0.0%
(9.1%)
0.0%
(39.5%)
0.0%
20.5%
 
 
(3.2%)
(69.9%)
(48.3%)
(30.6%)
71.6%
(100.0%)
0.0%
36.8%
0.0%
0.0%
 
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
173.7%
74.4%
67.2%
264.8%
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
3/31/2010
 
 
 
$51,190
$0
$7,547
$39,175
$0
$99,585
$6,816
$31,868
$12,426
$20,335
$0
$3,363
$0
$174,393
 
 
$31,410
$13,256
$5,708
$50,374
$24,951
$0
$0
$32,445
$0
$107,770
 
$0
$0
$0
$2
$0
$0
$28,025
$25,104
$66,622
$33,861
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
QoQ
 
 
 
50.5%
0.0%
130.5%
46.7%
0.0%
52.9%
3.8%
15.5%
(9.2%)
(6.0%)
0.0%
(25.6%)
0.0%
25.4%
 
 
(34.1%)
48.4%
(10.7%)
(20.0%)
173.7%
(100.0%)
0.0%
29.3%
0.0%
8.6%
 
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
180.6%
80.2%
67.1%
644.0%
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
Period Ending
Net Income
Operating Activities
Depreciation
Adjustments To Net Income
Changes In Accounts Receivables
Changes In Liabilities
Changes In Inventories
Changes In Other Operating Activities
Total from Operating Activities
Investing Activities
Capital Expenditures
Investments
Other Investing Activities
Total from Investing Activities
Financing Activities
Dividends Paid
Sale Purchase of Stock
Net Borrowings
Other Financing Activites
Total from Financing Activities
Effect of Exchange Rate Changes
Change in Cash and Cash Equivalents
12/31/2009
$1,265
 
$6,416
$45,428
($3,255)
$13,153
($12,457)
($249)
$50,301
 
($1,873)
($2,841)
($2,146)
($6,860)
 
($2,969)
$3,227
$1,307
$0
$1,565
$24
$45,029
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
YoY
(89.4%)
 
458.4%
714.9%
(3,600.0%)
106.5%
(165.3%)
45.8%
151.3%
 
53.6%
0.0%
87.8%
68.3%
 
(930.9%)
0.0%
(74.2%)
0.0%
(67.3%)
(96.4%)
1,083.4%
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
12/31/2008
$11,986
 
$1,149
$5,575
$93
$6,371
($4,695)
($459)
$20,020
 
($4,034)
$0
($17,633)
($21,667)
 
($288)
$0
$5,074
$0
$4,786
$665
$3,805
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
YoY
46.5%
 
32.2%
129.8%
(97.2%)
2,129.0%
(65.0%)
(176.6%)
63.3%
 
53.7%
0.0%
(16,379.4%)
(145.8%)
 
41.1%
0.0%
292.7%
0.0%
253.3%
56.8%
412.8%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Period Ending
Net Income
Operating Activities
Depreciation
Adjustments To Net Income
Changes In Accounts Receivables
Changes In Liabilities
Changes In Inventories
Changes In Other Operating Activities
Total from Operating Activities
Investing Activities
Capital Expenditures
Investments
Other Investing Activities
Total from Investing Activities
Financing Activities
Dividends Paid
Sale Purchase of Stock
Net Borrowings
Other Financing Activites
Total from Financing Activities
Effect of Exchange Rate Changes
Change in Cash and Cash Equivalents
6/30/2010
$12,878
 
$2,046
$4,455
($1,378)
$1,666
($2,068)
($337)
$17,262
 
($4,711)
$0
($2,511)
($7,222)
 
($83)
($3,653)
($1,495)
$0
($5,231)
$264
$5,073
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
QoQ
84.7%
 
17.5%
462.5%
(395.7%)
(79.3%)
(234.6%)
46.2%
(19.1%)
 
(435.9%)
100.0%
76.8%
41.2%
 
0.0%
(3,304.4%)
(123.6%)
0.0%
(181.3%)
1,420.0%
(67.2%)
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
3/31/2010
$10,606
 
$1,849
$1,074
($2,586)
($4,054)
($4,284)
($513)
$2,093
 
($1,443)
$0
($2,071)
($3,514)
 
($4,781)
$689
$2,914
$0
($1,178)
($55)
($2,654)
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
QoQ
46.1%
 
15.7%
164.5%
(224.5%)
(279.8%)
(21.9%)
(310.4%)
(70.4%)
 
(46.2%)
0.0%
(118.2%)
(133.8%)
 
0.0%
0.0%
(61.9%)
0.0%
(115.4%)
(175.3%)
(110.5%)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Period Ending
Total Revenue
Cost of Revenue
Gross Profit
Operating Expenses
Research Development
Selling General & Administrative
Non Recurring
Others
Total Operating Expenses
Operating Income or Loss
Income from Continuing Operations
Total Other Income/Expenses Net
Earnings Before Interest And Taxes
Interest Expense
Income Before Tax
Income Tax Expense
Minority Interest
Net Income From Continuing Ops
 
Non-recurring Events
Discontinued Operations
Extraordinary Items
Effect Of Accounting Changes
Other Items
Net Income
Preferred Stock And Other Adjustments
Net Income Applicable To Common Shares
12/31/2009
$118,998
$32,622
$86,376
 
$1,663
$23,336
$0
$0
$0
$61,377
 
($29,887)
$28,126
$0
$28,126
$10,513
($16,348)
$1,832
 
 
$0
$0
$0
$0
$1,265
$0
$1,265
  
  
  
  
 
  
  
  
  
  
  
 
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
YoY
154.5%
132.3%
164.1%
 
42.6%
108.2%
0.0%
0.0%
0.0%
201.8%
 
(11,807.2%)
38.8%
(100.0%)
41.4%
128.7%
(394.8%)
(84.7%)
 
 
0.0%
0.0%
0.0%
0.0%
(89.4%)
0.0%
(89.4%)
  
  
  
  
 
  
  
  
  
  
  
 
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
12/31/2008
$46,751
$14,041
$32,711
 
$1,166
$11,208
$0
$0
$0
$20,336
 
($251)
$20,260
$373
$19,886
$4,597
($3,304)
$11,986
 
 
$0
$0
$0
$0
$11,986
$0
$11,986
  
  
  
  
 
  
  
  
  
  
  
 
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
YoY
44.3%
41.2%
45.7%
 
91.5%
23.4%
0.0%
0.0%
0.0%
59.4%
 
33.1%
63.6%
174.3%
62.4%
121.5%
(65.9%)
46.5%
 
 
0.0%
0.0%
0.0%
0.0%
46.5%
0.0%
46.5%
  
  
  
  
 
  
  
  
  
  
  
 
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
Period Ending
Total Revenue
Cost of Revenue
Gross Profit
Operating Expenses
Research Development
Selling General & Administrative
Non Recurring
Others
Total Operating Expenses
Operating Income or Loss
Income from Continuing Operations
Total Other Income/Expenses Net
Earnings Before Interest And Taxes
Interest Expense
Income Before Tax
Income Tax Expense
Minority Interest
Net Income From Continuing Ops
 
Non-recurring Events
Discontinued Operations
Extraordinary Items
Effect Of Accounting Changes
Other Items
Net Income
Preferred Stock And Other Adjustments
Net Income Applicable To Common Shares
9/30/2010
$36,004
$10,269
$25,735
 
($1,154)
$8,062
$0
$0
$0
$18,827
 
$3,651
$22,290
$0
$22,290
$3,500
($5,115)
$13,998
 
 
$0
$0
$0
$0
$13,675
$0
$13,675
  
  
  
  
 
  
  
  
  
  
  
 
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
QoQ
33.2%
47.5%
28.2%
 
(538.8%)
39.3%
0.0%
0.0%
0.0%
34.2%
 
126.9%
9,161.0%
100.0%
9,161.0%
38.1%
(49.9%)
327.1%
 
 
0.0%
0.0%
0.0%
0.0%
320.8%
0.0%
320.8%
  
  
  
  
 
  
  
  
  
  
  
 
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
6/30/2010
$40,908
$9,059
$31,849
 
$1,317
$7,763
$0
$0
$0
$22,769
 
$2,168
$24,656
$0
$24,656
$5,087
($6,691)
$13,035
 
 
$0
$0
$0
$0
$12,878
$0
$12,878
  
  
  
  
 
  
  
  
  
  
  
 
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
QoQ
23.3%
(1.1%)
32.6%
 
257.9%
9.0%
0.0%
0.0%
0.0%
37.7%
 
323.5%
55.6%
(100.0%)
72.7%
70.6%
(54.7%)
88.1%
 
 
0.0%
0.0%
0.0%
0.0%
84.7%
(100.0%)
(15.3%)